{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
ciclesonide
to a specific field?
There is one exact (name or code) match for ciclesonide
Status:
US Approved Rx
(2006)
Source:
NDA022004
(2006)
Source URL:
First approved in 2006
Source:
NDA022004
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Ciclesonide is a glucocorticoid receptor agonist indicated for the treatment of allergic rhinitis (Omnaris nasal spray) and asthma (Alvesco). It was also developed by Byk Gulden for chronic obstructive pulmonary disease (COPD), but no development had been reported for this indication since 1999. Ciclesonide is a pro-drug and rapidly metabolized to C21-desisobutyryl-ciclesonide which is more potent toward GR receptor than the parent drug.
Showing 1 - 8 of 8 results
Status:
US Approved Rx
(2006)
Source:
NDA022004
(2006)
Source URL:
First approved in 2006
Source:
NDA022004
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Ciclesonide is a glucocorticoid receptor agonist indicated for the treatment of allergic rhinitis (Omnaris nasal spray) and asthma (Alvesco). It was also developed by Byk Gulden for chronic obstructive pulmonary disease (COPD), but no development had been reported for this indication since 1999. Ciclesonide is a pro-drug and rapidly metabolized to C21-desisobutyryl-ciclesonide which is more potent toward GR receptor than the parent drug.
Status:
Possibly Marketed Outside US
Source:
Octaplasma by Octapharma Pharmazeutika Produktionsges M B H [Canada]
Source URL:
First approved in 2013
Source:
BLA125416
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT03534063: Not Applicable Interventional Completed Pain, Postoperative
(2018)
Source URL:
Class:
PROTEIN
![Structure of (2′R)-2′-[(1RS)-cyclohex-3-enyl]-11β-hydroxy-3,20-dioxo-16βH-[1,3]dioxolo[4′,5′:16,17]pregna-1,4-dien-21-yl 2-methylpropanoate](/img/1a747bd4-fa91-42f3-985c-2e85f2055bef.svg?size=200&context=bfaiedtprj)
